Elevated intrathecal antibodies against the medium neurofilament subunit in multiple sclerosis
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- dospělí MeSH
- ELISA metody MeSH
- lidé středního věku MeSH
- lidé MeSH
- následné studie MeSH
- neurofilamentové proteiny imunologie MeSH
- protilátky krev mozkomíšní mok MeSH
- roztroušená skleróza krev mozkomíšní mok imunologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- neurofilament protein M MeSH Prohlížeč
- neurofilamentové proteiny MeSH
- protilátky MeSH
Neurofilaments are cytoskeletal proteins localized within axons, which may interact with the immune system during and following tissue destruction in multiple sclerosis (MS). Antibodies against the medium neurofilament subunit synthesized intrathecally may reflect axonal damage in MS patients. Both immunoglobulin G (IgG) and M (IgM) responses against the purified native medium subunit of neurofilaments (NFM) using enzyme-linked immunosorbent assay (ELISA) were determined in paired serum and cerebrospinal fluid samples obtained from 49 MS patients, 16 normal controls (CN), 21 control patients with miscellaneous diseases (CD) and 14 patients with neurodegenerative disorders (CDEG). Intrathecal production of IgM and IgG antibodies to NFM were elevated in MS patients compared with the CN or CD groups (p<0.04 for IgM, p<0.01 for IgG). The increase was present in all the MS courses (relapsing-remitting, primary and secondary progressive). Similar local anti-NFM IgG and IgM synthesis occurred in the MS and CDEG groups. MS patients with short and long disease duration did not differ in terms of their anti-NFM IgM and IgG responses. Repeated examinations showed stable intrathecal anti-NFM production. Intrathecal IgG and IgM antibodies against NFM were increased in MS patients and may serve as a potential marker for axonal pathology. The extent of anti-NFM levels did not correspond to any individualized clinical profiles of MS patients.
Zobrazit více v PubMed
Bioessays. 2003 Apr;25(4):346-55 PubMed
Acta Neuropathol. 1986;72(1):82-5 PubMed
J Neuroimmunol. 2002 Jan;122(1-2):132-9 PubMed
J Neuroimmunol. 2001 Jan 1;112(1-2):1-14 PubMed
Neurology. 2005 Apr 12;64(7):1144-51 PubMed
Neurology. 1996 Apr;46(4):907-11 PubMed
Neurology. 1998 May;50(5):1282-8 PubMed
Brain. 2002 Oct;125(Pt 10):2202-12 PubMed
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402-4 PubMed
Brain. 2003 Feb;126(Pt 2):433-7 PubMed
J Neurol. 2003 Dec;250(12 ):1407-19 PubMed
Neurobiol Aging. 1998 May-Jun;19(3):205-16 PubMed
J Neurol Sci. 2001 Mar 1;184(2):101-22 PubMed
Curr Opin Neurol. 2005 Jun;18(3):225-30 PubMed
Neurology. 2003 Dec 23;61(12):1720-5 PubMed
Brain. 2002 Aug;125(Pt 8):1676-95 PubMed
Neurology. 1983 Nov;33(11):1444-52 PubMed
Ann Neurol. 2000 Mar;47(3):391-5 PubMed
Neurology. 2002 May 14;58(9):1372-81 PubMed
Ann Neurol. 1983 Mar;13(3):227-31 PubMed
J Neurol. 2001 Dec;248(12):1019-29 PubMed
N Engl J Med. 1998 Jan 29;338(5):278-85 PubMed
J Neurol Sci. 1998 Feb 5;154(2):137-45 PubMed
Brain. 1997 Mar;120 ( Pt 3):393-9 PubMed
J Neuroimmunol. 2005 Apr;161(1-2):190-4 PubMed
Neurology. 2004 Nov 9;63(9):1586-90 PubMed
Ann Neurol. 2001 Jun;49(6):793-6 PubMed
Scand J Clin Lab Invest. 1977 Sep;37(5):397-401 PubMed
Arch Neurol. 2001 Jan;58(1):65-70 PubMed
J Neurol Neurosurg Psychiatry. 2005 Feb;76(2):206-11 PubMed
Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum
Increased intrathecal high-avidity anti-tau antibodies in patients with multiple sclerosis
